138907-82-1

Basic information

• Product Name: 1-(3-fluorophenyl)-1H-pyrazole-4-carboxylic acid
• Synonyms: 1-(3-fluorophenyl)-1H-pyrazole-4-carboxylic acid
• CAS NO: 138907-82-1
• Molecular Formula: C₁₀H₇FN₂O₂
• Molecular Weight: 206.1731832
• Mol File: 138907-82-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(3-fluorophenyl)-1H-pyrazole-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-fluorophenyl)-1H-pyrazole-4-carboxylic acid(138907-82-1)
• EPA Substance Registry System: 1-(3-fluorophenyl)-1H-pyrazole-4-carboxylic acid(138907-82-1)

Safety Data

• Hazardous Substances Data: 138907-82-1(Hazardous Substances Data)

Usage

Chemical class

Pyrazole derivative

Functional group

Carboxylic acid attached to the 4-position of the pyrazole ring

Substituent

Fluorophenyl group on the 1-position of the pyrazole ring

Structural features

Ability to interact with biological targets

Potential applications

Pharmaceutical applications as a building block for the synthesis of novel drug candidates

Research status

Further research needed to fully explore potential uses and properties

Upstream product

• 2924-16-5 3-fluorophenylhydrazine hydrochloride 
• 936940-82-8 1-(3-fluorophenyl)-1H-pyrazole-4-carbaldehyde 
• 138907-70-7 ethyl 5-amino-1-(3-fluorophenyl)-1H-pyrazole-4-carboxylate 

Relevant articles and documents

Design, synthesis and pharmacological evaluation of new anti-inflammatory compounds

Inflammatory diseases and pain are among the main problems that significantly influence the lifestyle of millions of people and existing therapies are not always effective and can cause several adverse effects. In this context, the molecular modifications or synthesis of compounds continue being the best strategies for the identification of new compounds for the treatment of pain and inflammation. The aim of this study was to evaluate the analgesic and anti-inflammatory activities of new analogues of pyrazole compounds containing subunits N-phenyl-1-H-pirazoles and 1,3,4-oxadiazole-2(3H)-thione, LQFM-146, LQFM-147 and LQFM-148. In the acetic acid-induced abdominal writhing test, treatments with LQFM-146, LQFM-147 or LQFM-148 at doses 89, 178 and 356?μmol/kg p.o. reduced the abdominal writhing in a dose-dependent manner. In the formalin test, these compounds at dose 178?μmol/kg p.o. reduced the licking time only in inflammatory phase of this test, suggesting an antinociceptive effect dependent of the anti-inflammatory effect. The treatment with the three compounds in intermediate dose (178?μmol/kg p.o.) reduced the edema at all tested time points in the carrageenan-induced paw edema test and reduced polymorphonuclears cell migration, activity myeloperoxidase and TNF-α levels in the carrageenan-induced pleurisy test. Our date suggest that the new compounds LQFM-146, LQFM-147 and LQFM-148 possess satisfactory anti-inflammatory and antinociceptive effects that involves the reduction of pro-inflammatory cytokines and inhibition of the myeloperoxidase enzyme.

Synthesis of pyrazole-carboxamides and pyrazole-carboxylic acids derivatives: Simple methods to access powerful building blocks

Hybrid systems containing pyrazole moiety show a wide spectrum of biological activities. To access novel hybrids with pyrazole ring, in this work we synthesized twenty pyrazole-carboxylic acids and twenty pyrazole-carboxamides, using simple synthetic methods, to be used as building blocks in the development of new structures.

PYRAZOLE CARBOXAMIDE DERIVATIVES AS TAAR MODULATORS FOR USE IN THE TREATMENT OF SEVERAL DISORDERS, SUCH AS DEPRESSION, DIABETES AND PARKINSON'S DISEASE

The present invention relates to compounds of formula (I) wherein R1 is phenyl, optionally substituted by halogen, lower alkyl, lower cycloalkyl, lower alkoxy, cyano, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, lower